226: Mastering Radiopharmaceutical Development: Preclinical Model Selection for Clinical Success with Bryan Miller - Part 2
Thu Feb 05 2026
Hard-to-treat cancers like pancreatic ductal adenocarcinoma (PDAC) have long defied conventional therapies. Radiopharmaceuticals, combining targeted therapy with diagnostic power, are creating new opportunities in precision oncology.
Host David Brühlmann speaks with Bryan Miller of Crown Bioscience, who explains how Crown's strategic partnerships, rigorous quality standards, and adaptive study design are shaping radiopharmaceutical development—delivering speed, safety, and real clinical impact.
In this episode, you'll learn:
The promise and practical implications of theranostics—agents used for both diagnosis and treatment (02:44)Definitions and distinctions between CDX (cell line-derived xenograft) and PDX (patient-derived xenograft) models, and why PDX models better recapitulate tumor heterogeneity (05:11)Strategies for building more predictive, clinically relevant research models (06:09)Balancing rapid innovation with rigorous quality standards—why robust QC systems enable speed without compromising safety (08:01)Key advice for scientists entering radiopharmaceutical development, including how to choose the right research partners (09:53)Why effective collaboration between biotech companies and CROs is akin to a well-chosen partnership (10:50)The future outlook for radiopharmaceuticals and their impact on hard-to-treat cancers (12:21)Strategic insight:
Focusing on theranostic radiopharmaceuticals—agents that combine diagnostics and therapy—offers a high-impact strategy for hard-to-treat cancers like PDAC. By enabling simultaneous patient stratification and targeted treatment, theranostics can accelerate development, improve clinical outcomes, and create a competitive advantage in areas where traditional therapies are limited.
Where do you see radiopharmaceuticals and advanced preclinical models making the biggest impact in oncology or beyond?
Explore the full conversation to learn how Bryan Miller and Crown Bioscience are scaling innovation for the next generation of cancer therapies.
Connect with Bryan Miller:
LinkedIn: www.linkedin.com/in/bryan-miller-148344aa
Crown Bioscience: www.crownbio.com
Next step:
Need fast CMC guidance? → Get rapid CMC decision support here
Support the show
More
Hard-to-treat cancers like pancreatic ductal adenocarcinoma (PDAC) have long defied conventional therapies. Radiopharmaceuticals, combining targeted therapy with diagnostic power, are creating new opportunities in precision oncology. Host David Brühlmann speaks with Bryan Miller of Crown Bioscience, who explains how Crown's strategic partnerships, rigorous quality standards, and adaptive study design are shaping radiopharmaceutical development—delivering speed, safety, and real clinical impact. In this episode, you'll learn: The promise and practical implications of theranostics—agents used for both diagnosis and treatment (02:44)Definitions and distinctions between CDX (cell line-derived xenograft) and PDX (patient-derived xenograft) models, and why PDX models better recapitulate tumor heterogeneity (05:11)Strategies for building more predictive, clinically relevant research models (06:09)Balancing rapid innovation with rigorous quality standards—why robust QC systems enable speed without compromising safety (08:01)Key advice for scientists entering radiopharmaceutical development, including how to choose the right research partners (09:53)Why effective collaboration between biotech companies and CROs is akin to a well-chosen partnership (10:50)The future outlook for radiopharmaceuticals and their impact on hard-to-treat cancers (12:21)Strategic insight: Focusing on theranostic radiopharmaceuticals—agents that combine diagnostics and therapy—offers a high-impact strategy for hard-to-treat cancers like PDAC. By enabling simultaneous patient stratification and targeted treatment, theranostics can accelerate development, improve clinical outcomes, and create a competitive advantage in areas where traditional therapies are limited. Where do you see radiopharmaceuticals and advanced preclinical models making the biggest impact in oncology or beyond? Explore the full conversation to learn how Bryan Miller and Crown Bioscience are scaling innovation for the next generation of cancer therapies. Connect with Bryan Miller: LinkedIn: www.linkedin.com/in/bryan-miller-148344aa Crown Bioscience: www.crownbio.com Next step: Need fast CMC guidance? → Get rapid CMC decision support here Support the show